Join

Compare · NVS vs QLGN

NVS vs QLGN

Side-by-side comparison of Novartis AG (NVS) and Qualigen Therapeutics Inc. (QLGN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVS and QLGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $277.58B, about 9711.4x QLGN ($28.6M).
  • Over the past year, NVS is up 29.1% and QLGN is down 8.6% - NVS leads by 37.7 points.
  • NVS has more recent analyst coverage (25 ratings vs 0 for QLGN).
PerformanceNVS+13.41%QLGN-8.57%
2025-09-30+0.00%2026-04-24
MetricNVSQLGN
Company
Novartis AG
Qualigen Therapeutics Inc.
Price
$145.43-1.37%
$3.20+5.09%
Market cap
$277.58B
$28.6M
1M return
-3.48%
-18.78%
1Y return
+29.12%
-8.57%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2015
News (4w)
0
0
Recent ratings
25
0
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

QLGN

Qualigen Therapeutics Inc.

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.

Latest NVS

Latest QLGN